Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA guanine-7 methyltransferase (RNMT) is a critical enzymatic subunit of the mRNA-capping methyltransferase complex (RNMT:RAMAC), responsible for the methylation of the N7 position of guanosine in the 5'-cap structure added to mRNA transcripts by RNA polymerase II. This cap methylation is essential for pre-mRNA processing, nuclear export, stabilization, and efficient translation. RNMT requires a cofactor (RAM) for maximal activity and proper localization. Its function is tightly regulated, for example by cell cycle-dependent phosphorylation, and it is essential for mammalian cell viability; loss of activity induces apoptosis. RNMT's central role in mRNA metabolism links it to cellular growth and survival, making it relevant in cancer and basic gene expression, but it is not commonly targeted by drugs as of now[1][3][4][7].
Catalyzes N7 methylation of the guanine cap at the 5' end of mRNA, which is essential for mRNA processing and function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA guanine-7 methyltransferase (RNMT).